Analysts said the deal shows Roche’s long-term strategy for its sequencing technology is “a clinical box for running NGS kits ...

The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.

"Freenome and Roche partner on cancer screening technology for ex-US markets" was originally created and published by Medical ...

Freenome, an early cancer detection company developing blood-based screening tests, today announced a strategic collaboration agreement with Roche to commercialize Freenome's cancer screening ...

Brisbane-based Freenome has locked in a second major partnership for its blood-based cancer screening test, this time with a ...

From a routine blood draw, Freenome’s diagnostics technology finds biological and genetic signs of cancer before they can be detected by currently available testing methods. A pivotal clinical trial ...

Freenome Holdings Inc. has landed $290 million from Basel, Switzerland-based Roche Holding AG to advance its multiomics platform for early cancer detection. The multimillion financing deal brings San ...

(Reuters) - Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple ...

Feb 15 (Reuters) - Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple ...